Get the Stockscreener App
7.96
1.53%
0.12
Aurinia Pharmaceuticals Inc stock is traded at $7.96, with a volume of 1.04M.
It is up +1.53% in the last 24 hours and down -3.05% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$7.84
Open:
$7.88
24h Volume:
1.04M
Relative Volume:
0.74
Market Cap:
$1.08B
Revenue:
$175.51M
Net Income/Loss:
$-78.02M
P/E Ratio:
-15.02
EPS:
-0.53
Net Cash Flow:
$-34.18M
1W Performance:
-1.49%
1M Performance:
-3.05%
6M Performance:
-12.53%
1Y Performance:
+46.86%
1-Day Range:
$7.80
$8.0089
1-Week Range:
$7.77
$8.25
52-Week Range:
$5.15
$10.67
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
7.96 | 1.10B | 175.51M | -78.02M | -34.18M | -0.53 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock? - MSN
Is The Options Market Predicting A Spike In Aurinia Pharmaceuticals (AUPH) Stock? - Barchart.com
(AUPH) Technical Data - news.stocktradersdaily.com
Aurinia Pharmaceuticals (AUPH) Reports Positive Lupkinis Trial Results | AUPH Stock News - GuruFocus
Aurinia Pharmaceuticals’ LUPKYNIS Shows Promising Results in Lupus Nephritis Study - TipRanks
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality - simplywall.st
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Aurinia Pharmaceuticals Inc. Just Recorded A 60% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Aurinia Pharmaceuticals Approves New Equity Incentive Plan - TipRanks
Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
Aurinia Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Transcript : Aurinia Pharmaceuticals Inc.Shareholder/Analyst Call - marketscreener.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Call Transcript - MSN
Aurinia Pharmaceuticals Financial Update and Strategic Growth Plans - Zenopa
Aurinia Pharmaceuticals (AUPH) Reports Strong Q1 Earnings Beat - GuruFocus
Aurinia outlines $250M–$260M 2025 revenue target as LUPKYNIS sales climb 25% and operational efficiency improves - MSN
Decoding Aurinia Pharmaceuticals Inc (AUPH): A Strategic SWOT In - GuruFocus
Company News for May 13, 2025 - Yahoo Finance
Aurinia Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Document - SEC.gov
Aurinia Pharmaceuticals Q1 2025 Earnings: Strong Growth Amid Challenges - TipRanks
Aurinia: Q1 Earnings Snapshot - MySA
Aurinia Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance - Benzinga
Leerink maintains Aurinia stock Outperform with $10 target - Investing.com
Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens - Investing.com India
AUPH Reports Q1 Revenue Exceeding Expectations with Strong Outlo - GuruFocus
Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Aurinia Pharmaceuticals' Q1 Swings to Profit, Revenue Rises; Reiterates 2025 Revenue Guidance - marketscreener.com
Aurinia Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Aurinia Pharmaceuticals Inc. Reiterates Guidance for the Full Year 2025 - marketscreener.com
Aurinia Pharmaceuticals Reports Strong First Quarter 2025 Financial Results - TipRanks
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 - Business Wire
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO Will Probably Find It Hard To See A Huge Raise This Year - simplywall.st
How the (AUPH) price action is used to our Advantage - news.stocktradersdaily.com
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025 - BioSpace
Glass Lewis Supports Aurinia’s Proposals for 2025 AGM - TipRanks
ISS Endorses Aurinia’s Proposals for 2025 Annual Meeting - TipRanks
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting - The Globe and Mail
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting - BioSpace
Aurinia Pharmaceuticals (AUPH) Gains Support from ISS for Board - GuruFocus
Aurinia Pharmaceuticals Inc expected to post earnings of 10 cents a shareEarnings Preview - TradingView
Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):